Roche Investing $700 M in New US Mfg Facility; $282 M in New Biomanufacturing Facility in China
Roche has announced plans to invest more than $700 million in a new 700,000-square-foot drug manufacturing facility in Holly Springs, North Carolina. Additionally, Roche has announced plans to build a new $282-million biomanufacturing facility in China.
The US project will add more than 400 manufacturing jobs when the site is operational and more than 1,500 construction jobs during site development. The new facility will support Roche’s future portfolio of obesity medicines. The company said that this initial investment could expand in the future based on business needs and the US policy environment.
Last month (April 2024), the company announced that it plans to invest $50 billion in existing and new research and development (R&D) and manufacturing facilities in its pharmaceuticals and diagnostics operations in the US in the next five years.
Roche current US footprint includes 13 manufacturing and 15 R&D sites across the company’s pharmaceutical and diagnostics divisions and 25,000 employees across eight US states.
The proposed new facility in China would have a construction area of about 25,000 square meters and would be located in Zhangjiang High-tech Park, Pudong New District, Shanghai. The project is expected to be officially completed in 2029 and officially put into production in 2031. The facility will be used for the localized production of Roshika (fariximab injection), an ophthalmic bispecific antibody drug.
